Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance

Journal of Infectious Diseases

Volumn 204, Issue 4, 2011, Pages 626-635

  Ben Ami, Ronen ^a   Garcia Effron, Guillermo ^c   Lewis, Russell E ^a,b   Gamarra, Soledad ^c   Leventakos, Konstantinos ^a   Perlin, David S ^c   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINOCANDIN; MACROPHAGE INFLAMMATORY PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CATALYSIS; CONTROLLED STUDY; ENZYME KINETICS; FEMALE; FITNESS; FKS1 GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS GROWTH; GENE MUTATION; GENE SEQUENCE; GROWTH RATE; HOMOZYGOSITY; IC 50; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; GENETIC FITNESS; MACROPHAGES; MICE; MUTATION; VIRULENCE;

EID: 79960884598     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir351     Document Type: Article

References (37)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17. (Pubitemid 39050477)
2. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142-51. (Pubitemid 37222342)
3. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35.
4. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50:2892-4. (Pubitemid 44198725)
5. Kurtz MB, Abruzzo G, Flattery A, et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 1996; 64:3244-51. (Pubitemid 26256172)
6. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49:3264-73. (Pubitemid 41060570)
7. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10:121-30. (Pubitemid 47031054)
8. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57:705-8.
9. Miller CD, Lomaestro BW, Park S, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006; 26:877-80. (Pubitemid 43807639)
10. Plaine A, Walker L, Da CG, et al. Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet Biol 2008; 45:1404-14.
11. Anderson JB. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 2005; 3:547-56. (Pubitemid 40903878)
12. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53:112-22.
13. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50:2058-63. (Pubitemid 43807526)
14. Robles JC, Koreen L, Park S, Perlin DS. Multilocus sequence typing is a reliable alternative method to DNA fingerprinting for discriminating among strains of Candida albicans. J Clin Microbiol 2004; 42:2480-8. (Pubitemid 38747494)
15. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of Yeasts. Approved Standard M27-A3. Wayne, PA: National Committee for Clinical Laboratory Standards, 2008.
16. Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, Kontoyiannis DP. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother 2010; 54:484-90.
17. Sekiya-Kawasaki M, Abe M, Saka A, et al. Dissection of upstream regulatory components of the Rho1p effector, 1,3-beta-glucan synthase, in Saccharomyces cerevisiae. Genetics 2002; 162:663-76. (Pubitemid 35365031)
18. Lehmann PF, White LO. Chitin assay used to demonstrate renal localization and cortisone-enhanced growth of Aspergillus fumigatus mycelium in mice. Infect Immun 1975; 12:987-92.
19. Toussaint M, Conconi A. High-throughput and sensitive assay to measure yeast cell growth: a bench protocol for testing genotoxic agents. Nat Protoc 2006; 1:1922-8. (Pubitemid 46773312)
20. Enjalbert B, Whiteway M. Release from quorum-sensing molecules triggers hyphal formation during Candida albicans resumption of growth. Eukaryot Cell 2005; 4:1203-10. (Pubitemid 41004133)
21. Chamilos G, Lionakis MS, Lewis RE, et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis 2006; 193:1014-22.
22. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86:973-83. (Pubitemid 26336801)
23. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2:e35.
24. Cowen LE, Kohn LM, Anderson JB. Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 2001; 183:2971-8. (Pubitemid 32433512)
25. Riggsby WS, Torres-Bauza LJ, Wills JW, Townes TM. DNA content, kinetic complexity, and the ploidy question in Candida albicans. Mol Cell Biol 1982; 2:853-62. (Pubitemid 12062447)
26. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 2008; 4:e1000040.
27. Munro CA, Selvaggini S, de Bruijn I, et al. The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. MolMicrobiol 2007; 63:1399-413.
28. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50:3160-1. (Pubitemid 44396427)
29. McKenzie CG, Koser U, Lewis LE, et al. Contribution of Candida albicans cell wall components to recognition by and escape from murine macrophages. Infect Immun 2010; 78:1650-8.
30. Da Silva CA, Chalouni C, Williams A, Hartl D, Lee CG, Elias JA. Chitin is a size-dependent regulator of macrophage TNF and IL-10 production. J Immunol 2009; 182:3573-82.
31. de Jong R, Thomma BP. Fungal LysM effectors: extinguishers of host immunity? Trends Microbiol 2009; 17:151-7.
32. Spellberg B, Ibrahim AS, Edwards JE Jr., Filler SG. Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis 2005; 192:336-43. (Pubitemid 40993405)
33. Cowen LE, Nantel A, Whiteway MS, et al. Population genomics of drug resistance in Candida albicans. Proc NatlAcad SciUSA2002; 99:9284-9. (Pubitemid 34764605)
34. DeRisi J, van den HB, Marc P, et al. Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants. FEBS Lett 2000; 470:156-60.
35. Rogers PD, Barker KS. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother 2003; 47:1220-7. (Pubitemid 36368578)
36. Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother 2010; 54:2655-9.
37. Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005; 49:3616-23. (Pubitemid 41233008)